A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Non-Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
In this study, the safety and tolerability of GNC-038 in participants with recurrent or
refractory Non-Hodgkin lymphoma will be investigated to assess the dose-limiting toxicity
(DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached
of GNC-038. The recommended dose for future clinical study will also be determined.